Premium
Targeting prostate cancer bone metastases
Author(s) -
Logothetis Christopher,
Tu ShiMing,
Navone Nora
Publication year - 2003
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.11130
Subject(s) - medicine , prostate cancer , prostate , radiation therapy , oncology , chemotherapy , targeted therapy , doxorubicin , carcinoma , cancer , radiology
Bone metastases are reported to account for a substantial portion of the symptoms from prostate carcinoma. Thus, many investigators have targeted this site of metastases in the hopes of achieving palliation of symptoms. These efforts have included the use of androgen ablation, radiopharmaceuticals, focal radiation, and chemotherapy. Preliminary clinical data support the fact that bone‐targeting therapy can be beneficial using multiple modalities. In the current study, the authors observed that selected patients with advanced androgen‐independent prostate carcinoma who received consolidation bone‐targeted therapy comprised of strontium‐89 with weekly doxorubicin after induction chemotherapy had a longer survived compared with those who did not receive bone‐targeted therapy.